Navigation Links
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
Date:7/27/2009

, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factor
'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
9. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
10. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 19, 2014 ... ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition ... 2014-2018" report to their offering. ... involves the study of chromosomes using molecular ... of genes and chromosomes. It plays a ...
(Date:9/18/2014)...  Low T Center endorses the recommendations of ... Hyattsville, Maryland earlier this week. The FDA ... population for testosterone therapy (TRT), as well as ... recent claims from studies that TRT affects cardiovascular ... do not provide convincing evidence that TRT is ...
(Date:9/18/2014)... KANSAS CITY, Kan. , Sept. 18, 2014 ... ), a pet therapeutics company focused on licensing, ... animals, today announced the full exercise of the ... common stock in connection with the company,s previously ... stock.  All of the shares are being offered ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... VIEW, Calif., Dec. 21, 2010 MAP Pharmaceuticals, Inc. (Nasdaq: ... ™ open-label safety trial.  The Company has now completed ... (NDA) for LEVADEX and plans to submit an NDA in ... inhaled migraine therapy that has completed Phase 3 clinical development ...
... -- China Botanic Pharmaceutical Inc. (AMEX: CBP ... and distributor of botanical products, bio-pharmaceuticals and traditional Chinese ... considerable progress in its efforts to comply with the ... 404") for fiscal year 2010. As announced ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3China Botanic Announces Progress on its SOX 404 Compliance Program 2China Botanic Announces Progress on its SOX 404 Compliance Program 3
(Date:9/19/2014)... September 19, 2014 September 1, 2014 ... will introduce its state-of-the-art, fiber based, Smart Private Network ... implementation begins in Tahlequah, Oklahoma, which is the capital ... connecting facilities within the Tahlequah area for the remainder ... educational institutions within the fourteen counties of the Cherokee ...
(Date:9/19/2014)... 19, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Potassium Chloride . , ... recalled one lot of Potassium Chloride Injection 10mEq ... cartons. Potassium Chloride, administered intravenously, is used to treat potassium ... on a labeling error on the shipping cartons in a ...
(Date:9/19/2014)... 2014 Mount Pleasant Retirement Village ... Health and Well-Being Coach Christi Hall to campus. , Hall’s ... brain tumors and gaining weight as a result of years ... and learning about nutrition. One year later she had lost ... her strength, endurance and cardio. , After joining the YMCA ...
(Date:9/19/2014)... Final Cut Pro X plugin and effects manufacturer, ... template for Apple's Final Cut Pro X . , ... FCPX users to create a professional themed video with ease ... Pixel Film Studios, "With 48 camera options and On-Screen controls, ... Theme." , Float features all of the tools needed ...
(Date:9/19/2014)... Washington, D.C. (PRWEB) September 19, 2014 ... in Madison County Circuit Court (case 14-L-1175), following a ... Carole Owen is suing DePuy Orthopaedics Inc. and ... product was defective. Flood Law Group, a nationally known ... and has been following developments in litigation involving defective ...
Breaking Medicine News(10 mins):Health News:The Cherokee Nation and RBSC sign a “Memorandum of Agreement” That Brings Smart Connect to the Cherokee Nation 2Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Pixel Film Studios Releases Float Theme for Final Cut Pro X Users 2Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2
... released today by the Association for Psychological Science: , , ... 65; in 2000 that number had jumped to 12.6 percent; and ... in that category. , , Cognitive decline was long ... seen a surge of interest in activities and products touted to ...
... Arcadia Resources, Inc. (NYSE Amex: KAD ... and pharmacy services under the Arcadia HealthCare(SM) brand, has ... Co., as Vice President of DailyMed(TM) Pharmacy Operations , ... the Indianapolis pharmacy operations, manage system integration within DailyMed ...
... Region recognizes immediate, ... ... Center and CHRISTUS St. Vincent Medical Group in Santa Fe, New Mexico, through teamwork, focused ... in nine months. CHRISTUS Health began managing CHRISTUS St. Vincent in April 2008 and ...
... health communications company StayWell Custom Communications (SCC), a division ... Grocer magazine to publish the white paper ... the Economy" to spotlight the retail sector,s growing need ... , , The white paper is a ...
... to include " Oncology Therapeutic ... , , - Center will train pharmacists to specialize in ... 23 Medco Health Solutions, Inc. (NYSE: MHS ), joined ... at AllPoints at Anson will house the Medco Therapeutic Resource Center(R) ...
... diagnostics market is poised for expansion with segments such ... potential. Heightened efforts to generate awareness about diabetes and ... development. For instance, limited awareness about HbA1C tests is ... curtailed with more education about the test. , ...
Cached Medicine News:Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 2Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 2Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 4Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 3Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 2Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 3Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 2Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: